Literature DB >> 22783954

Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.

Jianjun Chen1, Sunjoo Ahn, Jin Wang, Yan Lu, James T Dalton, Duane D Miller, Wei Li.   

Abstract

Novel ABI-III compounds were designed and synthesized based on our previously reported ABI-I and ABI-II analogues. ABI-III compounds are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compound having an average IC(50) value of 3.8 nM. They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance. ABI-III analogues maintain their mechanisms of action by inhibition of tubulin polymerization.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22783954      PMCID： PMC3426659          DOI： 10.1021/jm300564b

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  26 in total

1.  Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

Authors:  Giuseppe La Regina; Ruoli Bai; Willeke Rensen; Antonio Coluccia; Francesco Piscitelli; Valerio Gatti; Alessio Bolognesi; Antonio Lavecchia; Ilaria Granata; Amalia Porta; Bruno Maresca; Alessandra Soriani; Maria Luisa Iannitto; Marisa Mariani; Angela Santoni; Andrea Brancale; Cristiano Ferlini; Giulio Dondio; Mario Varasi; Ciro Mercurio; Ernest Hamel; Patrizia Lavia; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2011-11-21       Impact factor: 7.446

2.  Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.

Authors:  Pascale Barbier; Audrey Dorléans; Francois Devred; Laura Sanz; Diane Allegro; Carlos Alfonso; Marcel Knossow; Vincent Peyrot; Jose M Andreu
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

3.  Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Andrea Brancale; Antonio Ricci; Ernest Hamel; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2011-06-27       Impact factor: 7.446

4.  Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.

Authors:  Chien-Ming Li; Jianjun Chen; Yan Lu; Ramesh Narayanan; Deanna N Parke; Wei Li; Sunjoo Ahn; Duane D Miller; James T Dalton
Journal:  Drug Metab Dispos       Date:  2011-07-08       Impact factor: 3.922

5.  Identification and biological activities of new taccalonolide microtubule stabilizers.

Authors:  Jiangnan Peng; April L Risinger; Gary A Fest; Evelyn M Jackson; Gregory Helms; Lisa A Polin; Susan L Mooberry
Journal:  J Med Chem       Date:  2011-08-11       Impact factor: 7.446

6.  Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents.

Authors:  Yan Lu; Chien-Ming Li; Zhao Wang; Jianjun Chen; Michael L Mohler; Wei Li; James T Dalton; Duane D Miller
Journal:  J Med Chem       Date:  2011-06-07       Impact factor: 7.446

Review 7.  Microtubule-binding agents: a dynamic field of cancer therapeutics.

Authors:  Charles Dumontet; Mary Ann Jordan
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

8.  Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor.

Authors:  Chien-Ming Li; Zhao Wang; Yan Lu; Sunjoo Ahn; Ramesh Narayanan; Jeffrey D Kearbey; Deanna N Parke; Wei Li; Duane D Miller; James T Dalton
Journal:  Cancer Res       Date:  2010-11-16       Impact factor: 12.701

9.  Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.

Authors:  Jianjun Chen; Chien-Ming Li; Jin Wang; Sunjoo Ahn; Zhao Wang; Yan Lu; James T Dalton; Duane D Miller; Wei Li
Journal:  Bioorg Med Chem       Date:  2011-07-01       Impact factor: 3.641

10.  Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

Authors:  Bernard L Flynn; Gurmit S Gill; Damian W Grobelny; Jason H Chaplin; Dharam Paul; Annabell F Leske; Tina C Lavranos; David K Chalmers; Susan A Charman; Edmund Kostewicz; David M Shackleford; Julia Morizzi; Ernest Hamel; M Katherine Jung; Gabriel Kremmidiotis
Journal:  J Med Chem       Date:  2011-08-05       Impact factor: 7.446
View more
  28 in total

1.  2-(3'-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and evaluation of antibacterial and anticancer activities.

Authors:  Mukund P Tantak; Jing Wang; Rajnish Prakash Singh; Anil Kumar; Kavita Shah; Dalip Kumar
Journal:  Bioorg Med Chem Lett       Date:  2015-08-06       Impact factor: 2.823

2.  Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Authors:  Souvik Banerjee; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Shanshan Deng; Lei Yang; Guo-Bo Li; Jinliang Yang; Stephen W White; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2018-02-12       Impact factor: 7.446

3.  Structures of potent anticancer compounds bound to tubulin.

Authors:  Dan E McNamara; Silvia Senese; Todd O Yeates; Jorge Z Torres
Journal:  Protein Sci       Date:  2015-05-27       Impact factor: 6.725

Review 4.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

5.  Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.

Authors:  Min Xiao; Sunjoo Ahn; Jin Wang; Jianjun Chen; Duane D Miller; James T Dalton; Wei Li
Journal:  J Med Chem       Date:  2013-04-09       Impact factor: 7.446

6.  An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.

Authors:  Shanshan Deng; Raisa I Krutilina; Qinghui Wang; Zongtao Lin; Deanna N Parke; Hilaire C Playa; Hao Chen; Duane D Miller; Tiffany N Seagroves; Wei Li
Journal:  Mol Cancer Ther       Date:  2019-10-23       Impact factor: 6.261

7.  Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.

Authors:  Ruinan Yang; Goutam Mondal; Rachel A Ness; Kinsie Arnst; Vaibhav Mundra; Duane D Miller; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2017-01-24       Impact factor: 9.776

8.  Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.

Authors:  Qinghui Wang; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Dejian Ma; Hao Chen; Zhongzhi Wu; Jinliang Yang; Stephen W White; Duane D Miller; Wei Li
Journal:  J Med Chem       Date:  2018-08-30       Impact factor: 7.446

9.  Synthesis of 5,7-disubstituted-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-amines as microtubule inhibitors.

Authors:  Aleem Gangjee; Sonali Kurup; Charles D Smith
Journal:  Bioorg Med Chem       Date:  2013-01-03       Impact factor: 3.641

10.  Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.

Authors:  Jin Wang; Wei Li
Journal:  J Pharmacol Exp Ther       Date:  2014-03-12       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.